115P Immune-related adverse events in cancer patients treated with immune checkpoint inhibitors in Germany: A population-based study

GroupB Pembrolizumab.The primary endpoints were overall survival (OS) and progression-free survival (PFS), with adverse events (AEs) as secondary endpoints.A pvalue of <0.05 was considered significant.Results: From August 2019 to July 2024, we identified 30 pts.Of those, 53% were in GroupA and 47% in GroupB.Most had transitional cell carcinoma, with 77% from the lower urinary tract and 47% having lymph node-only disease.The median number of PBC cycles was 6, with 40% ineligible for cisplatin.After a median follow-up of 19.9 months (mo) for GroupA and 18.7 mo for GroupB, the mOS was 25 mo and 29.5 mo, respectively (p0.52) and the mPFS of immunotherapy was 14 mo and 8 mo, respectively (p0.51).The median time from the end of PBC and the start of Pembrolizumab was 4.1 mo, with a median treatment duration of 7.6 mo for GroupA and 3.5 mo for GroupB.At the time of data analysis, 40% (n12) of pts were alive and 33% (n10) on treatment, with 40% still receiving Avelumab, and 50% and 10% on subsequent therapies after Avelumab and Pembrolizumab, respectively.In both groups 50% of pts have a neutrophil-to-lymphocyte ratio (NLR) 3 at baseline of PBC.NLR ratio negatively correlates with OS (p0.099) and PFS (p0.047).Both treatments were well tolerated, with Grade 3 AEs in 1 pt on Avelumab and 3 on Pembrolizumab, and no Grade 4 AEs reported.Conclusions: Group A and Group B showed no statistically significant differences in OS and PFS.Of note, more pts were on Avelumab treatment at the data cutoff.AEs were similar in the two groups.Further investigation and follow-up are warranted to gain definitive conclusions on optimal mUC management in the era of immunotherapy and immunoconjugates.